Chimeric Therapeutics Limited · ASX:CHM
Chimeric Therapeutics — ASCO 2021
7 slides from Chimeric Therapeutics's conference presentation, Jun 4, 2021
Slide 1: A Phase 1 Study to Evaluate CLTX CAR T Cells for MMP2+ Recurrent or Progressive Glioblastoma
A PHASE 1 STUDY TO EVALUATE CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS INCORPORATING A CHLOROTOXIN TUMOR-TARGETING DOMAIN FOR PATIENTS WITH MMP2+ RECURRENT OR PROGRESSIVE GLIOBLASTOMA (NCT04214392) Christine Brown, PhD Professor in Hem/HCT and Immuno-Oncology Deputy Director, T Cell Therapeutics Resear
Slide 2: Background
Background • Glioblastoma (GBM) is the most common and aggressive adult malignant brain tumor1 and has substantial heterogeneity2 • GBM has a 5-year survival rate of 5.1%3 and a median OS of 5-8 months following recurrence4,5 • No effective standard of care for recurrent GBM exists; treatment option
Slide 3: Novel Features of CLTX-CAR T-Cell Therapy
Novel Features of CLTX-CAR T-Cell Therapy CLTX-CAR T-cell therapy (CLTX(EQ)28ζ/CD19t+ T cells) uses CLTX as the tumor-recognition domain that identifies a multireceptor complex containing MMP2 for binding on GBM cells Novel receptor-binding Negligible killing of domain normal human cell lines, suppo
Slide 4: CLTX-CAR T Cells Mediate Potent In Vivo Antitumor Activity
CLTX-CAR T Cells Mediate Potent In Vivo Antitumor Activity Tumor regression was observed in in vivo orthotopic GBM-xenograft mouse models after adoptive transfer of CLTX-CAR T cells via the ICT route • Quantification of ffLuc flux (photons/sec) for each mouse • Significantly improved survival follow
Slide 5: Phase 1 Study Design
Phase 1 Study Design Primary Endpoints: Toxicity, including DLTs, CRS, and all other toxicities; determine the MTD schedule and RP2D plan Secondary Endpoints: • CAR T-cell and endogenous T-cell levels; phenotype; and cytokine levels in PB, TCF, and CSF • 6-month PFS rate, 9-month OS rate, and median
Slide 6: Phase 1 Treatment Schema
Phase 1 Treatment Schema • In a preliminary safety lead-in phase, patients are treated in Arm 1 and will receive a low dose of chlorotoxin-CAR T cells through the ICT catheter only • Patients will then be treated in Arm 2 in which CAR-T cells are administered both ICT and ICV via dual delivery; dose
Slide 7: Conclusions and Future Directions
Conclusions and Future Directions • CLTX-CAR T-cell therapy is a novel immunotherapy that has the potential to extend the range of solid tumors targetable by CAR T cells and has the scope to deliver a broad immuno-oncology platform • Results from our phase 1 study are expected to demonstrate the saf